MYCN oncoprotein targets and their therapeutic potential.
about
NeuroblastomaDickkopf-3 is regulated by the MYCN-induced miR-17-92 cluster in neuroblastomaSparstolonin B, a novel plant derived compound, arrests cell cycle and induces apoptosis in N-myc amplified and N-myc nonamplified neuroblastoma cellsAdaptation of phenylalanine and tyrosine catabolic pathway to hibernation in batsMechanisms limiting body growth in mammalsPEA15 impairs cell migration and correlates with clinical features predicting good prognosis in neuroblastomaUnveiling MYCN regulatory networks in neuroblastoma via integrative analysis of heterogeneous genomics data.Conditional expression of retrovirally delivered anti-MYCN shRNA as an in vitro model system to study neuronal differentiation in MYCN-amplified neuroblastoma.The REST gene signature predicts drug sensitivity in neuroblastoma cell lines and is significantly associated with neuroblastoma tumor stage.Tumour-suppressor microRNAs let-7 and mir-101 target the proto-oncogene MYCN and inhibit cell proliferation in MYCN-amplified neuroblastoma.MYCN-dependent expression of sulfatase-2 regulates neuroblastoma cell survival.Therapeutic targets for neuroblastomas.Vorinostat increases expression of functional norepinephrine transporter in neuroblastoma in vitro and in vivo model systems.Reorganization of metastamiRs in the evolution of metastatic aggressive neuroblastoma cellsMYCN amplification confers enhanced folate dependence and methotrexate sensitivity in neuroblastoma.Functional MYCN signature predicts outcome of neuroblastoma irrespective of MYCN amplification.DNA polymerase β variant Ile260Met generates global gene expression changes related to cellular transformation.HDAC inhibitors suppress c-Jun/Fra-1-mediated proliferation through transcriptionally downregulating MKK7 and Raf1 in neuroblastoma cells.Type III TGF-β receptor promotes FGF2-mediated neuronal differentiation in neuroblastoma.Neuroblastoma treatment in the post-genomic era.Apoptotic cell death in neuroblastoma.MYCN-mediated transcriptional repression in neuroblastoma: the other side of the coin.Dissection of the oncogenic MYCN transcriptional network reveals a large set of clinically relevant cell cycle genes as drivers of neuroblastoma tumorigenesis.Overexpression of MYCN promotes proliferation of non-small cell lung cancer.MYCN-mediated miR-21 overexpression enhances chemo-resistance via targeting CADM1 in tongue cancer.NSCLC Driven by DDR2 Mutation Is Sensitive to Dasatinib and JQ1 Combination Therapy.CDK4 inhibition restores G(1)-S arrest in MYCN-amplified neuroblastoma cells in the context of doxorubicin-induced DNA damage.The MYCN Protein in Health and Disease.Synthetic lethal hubs associated with vincristine resistant neuroblastoma.Transcriptome sequencing of neonatal thymic epithelial cells.N-Myc overexpression increases cisplatin resistance in neuroblastoma via deregulation of mitochondrial dynamics.p53, SKP2, and DKK3 as MYCN Target Genes and Their Potential Therapeutic Significance.Targeting the MYCN-PARP-DNA Damage Response Pathway in Neuroendocrine Prostate Cancer.SHH, WNT, and NOTCH pathways in medulloblastoma: when cancer stem cells maintain self-renewal and differentiation properties.Prognostic significance of MYCN gene amplification and protein expression in primary brain tumors: Astrocytoma and meningioma.Reciprocal antagonistic regulation of N-myc mRNA by miR‑17 and the neuronal-specific RNA-binding protein HuD.MYCN is a novel oncogenic target in adult B-ALL that activates the Wnt/β-catenin pathway by suppressing DKK3.MYCN concurrence with SAHA-induced cell death in human neuroblastoma cells.Advances in the Surgical Treatment of Neuroblastoma
P2860
Q24617733-06F03508-4BB3-49AC-BD98-8345983C9BC0Q28117269-22052903-D6E8-42C2-BBDE-177D5D11E4A5Q28538332-0DAA4EE7-0B65-4D50-A7EF-DC7A381F7EF4Q28708926-82AF4B64-3153-42B5-AB04-058731EBA982Q28728958-F6D55FE8-3FC9-4D54-AE2F-A15953FE8AAAQ30417536-F1BC807A-0800-43B3-9F59-CEDA56BAFDC5Q31095310-3D7B6BFD-1731-43E2-AF58-8ABF648D5D3AQ33782749-5DB41F8F-0651-4B59-BB93-8E05B58FA232Q34072154-7428963D-125D-4344-818B-9C79BF2EC045Q34191041-82A81BFD-15C2-4FE5-9A42-C0DA81AAC5A6Q34438510-22EB9463-A943-45CB-85E0-84BB5A4B0EEFQ34560877-FF36B08B-7390-4BC7-8504-ECC2BDF9735DQ35637861-75F27744-EE88-4E70-84AD-BD946B97C647Q35684427-EA627450-FFEC-49C7-9D2C-A4BD556044A2Q36021061-08D3BDBC-FCFF-4E25-9F66-384749CABC6DQ36437048-AAE1AAA9-F942-4313-9C7F-CBA72A8D148FQ36727506-97BA87DC-B178-4B5A-9DDC-F57C688C159AQ36916322-9A0D492B-2BCE-4F32-AA2C-8E4D2949BC37Q37259264-1A1388D5-EDCD-419E-8A5E-E1B6CA4A9744Q37633731-E3F1E4D9-E2AA-4105-911E-1B2925B34375Q37679253-BDDB1CB8-A9B6-4479-BD10-2503F2E9FE5EQ38088637-5B7ECED2-2667-4554-9B42-7D150AC94C27Q38335300-AC53E746-B4AF-4BD3-A727-8D377CEEE273Q38736893-481E67F1-DECF-4C72-84C5-FFCFAA16E405Q38779984-CBAB2102-87B8-4D8E-AFB5-EAA37630F85DQ38849817-76C87721-5452-47F8-A08E-E02CBF9E5269Q39185185-0671219D-8A5C-487B-93E9-27442B0EC51DQ39208675-74DE93BE-E24D-4597-B9F0-E2CB7ED206E5Q39638600-CA04CC0E-3580-4CB8-AFB6-911ADE6DC339Q40779413-ED544A78-D7EC-412F-9AA7-B93EF1E3D430Q41857674-253A753B-3897-4333-A9FE-03AE3CF25B38Q42362115-CC917D5E-9231-4696-9BE9-5A766AAAA88BQ47595568-A6B18644-C083-4B2F-8BE6-566D4DB01D1EQ50673128-00D095CC-1317-47D5-A84D-80C6DF49AE2EQ50692461-53A15C44-95FA-497D-9A2E-A7BA20D1D286Q50969926-3EB66FF2-9252-46DE-816D-1EF6C03A0187Q52577596-FB2C593D-E20E-49E1-B29B-4712BCDBF2D4Q53372821-C7507C6E-AD50-4E61-B342-6CDAB07F82FCQ56979440-1EC0DF9A-0255-42E7-BDC8-0643C5DBA7A0
P2860
MYCN oncoprotein targets and their therapeutic potential.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 13 February 2010
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
MYCN oncoprotein targets and their therapeutic potential.
@en
MYCN oncoprotein targets and their therapeutic potential.
@nl
type
label
MYCN oncoprotein targets and their therapeutic potential.
@en
MYCN oncoprotein targets and their therapeutic potential.
@nl
prefLabel
MYCN oncoprotein targets and their therapeutic potential.
@en
MYCN oncoprotein targets and their therapeutic potential.
@nl
P2093
P1433
P1476
MYCN oncoprotein targets and their therapeutic potential.
@en
P2093
Deborah A Tweddle
Glenn M Marshall
John Lunec
Lindi Chen
P304
P356
10.1016/J.CANLET.2010.01.015
P407
P577
2010-02-13T00:00:00Z